H2ID to build Hadera desal plant

In their bid, H2ID offered to provide 100 million cubic meters of water per year through reverse osmosis polymer filtration at a winning price of NIS 2.56 per cubic meter.

By DANIEL KENNEMER
September 19, 2006 08:50

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

The H2ID consortium - bringing together the Delek Group's desalination engineering subsidiary and the Housing and Construction firm - has won a tender to build the Hadera desalination plant at an estimated cost of NIS 1.4 billion, the National Infrastructures Ministry said Monday. In their bid, H2ID offered to provide 100 million cubic meters of water per year through reverse osmosis polymer filtration at a winning price of NIS 2.56 per cubic meter. The bid compared favorably to the NIS 2.75 per cubic meter price at Ashkelon reverse osmosis plant opened in August 2005. The new plant - to be built through a 25-year BOT (build-operate-transfer) contract - is expected to begin operating in 2009.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS